GlassScriptPhysician profile
Korey Richard Graettinger
NPI 1497997209
$5,588.37
in general payments reported to CMS, 2019-2025
24 companies · $699 in 2025
The $699 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $611 · 2023: $1,137 · 2024: $3,140 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,680 · Travel and Lodging: $1,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,680.18 |
| Travel and Lodging | $1,296.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,852.56 | 2024-2025 | Linq II, Pulseselect |
| Boston Scientific Corporation | $1,563.91 | 2022-2025 | Watchman Flx, Watchman Access System, Cds - Mct/Cem Monitoring |
| Atricure, INC. | $658.31 | 2023-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $266.00 | 2022-2025 | Lifevest |
| Biosense Webster, INC. | $211.15 | 2022-2025 | Carto 3 |
| Philips North America LLC | $191.49 | 2023-2025 | Ambulatory Monitoring & Diagnostics Undivided, (5091) Amb Mon & Diag Und |
| Edwards Lifesciences Corporation | $144.03 | 2023-2024 | Hemosphere, Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $95.23 | 2022-2024 | Verquvo, Keytruda |
| Pfizer INC. | $95.01 | 2022-2025 | |
| Cvrx, INC. | $63.61 | 2022-2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $56.49 | 2023-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $55.61 | 2022-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $42.17 | 2022-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.45 | 2023-2024 | Jardiance |
| Tersera Therapeutics LLC | $33.53 | 2025 | Quzyttir |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $31.37 | 2022-2024 | |
| Lexicon Pharmaceuticals, INC. | $30.70 | 2024 | |
| Stryker Corporation | $28.93 | 2024 | Spy-Phi System |
| Sanofi-Aventis U.S. LLC | $28.05 | 2023 | |
| Kestra Medical Technology Services, INC. | $23.69 | 2023 | Assure Wcd |
| Biotronik INC. | $23.05 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.52 | 2023 | |
| Solventum Corporation | $20.98 | 2024 | Prevena |
| Altathera Pharmaceuticals LLC | $14.53 | 2025 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Korey Graettinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.